journal article·2023-04Open access

“Cluster Bomb” Based Bismuth Nano‐in‐Micro Spheres Formed Dry Powder Inhalation for Thermo‐Radio Sensitization Effects of Lung Metastatic Breast Cancer

Qiyue Wang, Ji Liu, Daquan Chen, Si Miao, Jing Wen, Chang Liu, Shushu Xue, Yang Liu, Qingjie Zhang, Yan Shen

Advanced Healthcare Materials· Volume 12· Issue 11

Abstract

Abstract Lung metastatic breast cancer (LMBC) is mainly diagnosed through CT imaging and radiotherapy could be the most common method in the clinic to inhibit tumor proliferation. While the sensitivity of radiotherapy is always limited due to the hypoxic tumor microenvironment and high doses of irradiation easily induce systemic cytotoxicity. Metal‐based materials applied as radiosensitizers have been widely investigated to improve efficiency and reduce the doses of irradiation. Herein, it is aimed to overcome these problems by designing biodegradable lipid‐camouflaged bismuth‐based nanoflowers (DP‐BNFs) as both a photo‐thermo‐radiosensitizer to develop a novel photothermal therapy (PTT) and radiotherapy combination strategy for LMBC treatment. To achieve effective lung deposition, “Cluster Bomb” structure‐based DP‐BNFs nano‐in‐micro dry powder inhalation (DP‐BNF@Lat‐MPs) are formulated through spray‐dried technology. The DP‐BNFs “cluster” in the microsphere to improve their tumor‐targeted lung deposition with a high fine particle fraction followed by burst releasing of DP‐BNFs for targeting delivery and LMBC therapy. The DP‐BNF@Lat‐MPs exhibit excellent photothermal conversion efficiency, radiotherapy enhancement, and CT imaging ability in vitro, which synergistically inhibit cell proliferation and metastasis. In vitro and in vivo data prove that combining PTT and radiotherapy with DP‐BNF@Lat‐MPs as a thermo‐radio dual‐sensitizer significantly enhances LMBC tumor metastasis inhibition with good biocompatibility and low toxicity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Inhalation and Respiratory Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Science Nanjing Tech University Nanjing 211816 China

Department of Pharmaceutics State Key Laboratory of Nature Medicines China Pharmaceutical University Nanjing 210009 China

School of Pharmacy Yantai University 30 Qingquan Road Yantai 264005 China

Department of Pharmacy Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University Nanjing 210009 China

Funding

National Natural Science Foundation of China · China Pharmaceutical University

References (44)

Show source-provided references
1. 10.1001/jama.2018.1932310.1001/jama.2018.19323 ↗
2. 10.1038/s41416-020-01161-410.1038/s41416-020-01161-4 ↗
3. 10.1186/s13058-015-0665-110.1186/s13058-015-0665-1 ↗
4. 10.7150/jca.1094410.7150/jca.10944 ↗
5. 10.1038/nrclinonc.2015.12010.1038/nrclinonc.2015.120 ↗
6. 10.1021/acsnano.7b0473710.1021/acsnano.7b04737 ↗
7. 10.1038/nrc395810.1038/nrc3958 ↗
8. 10.1002/adma.20170099610.1002/adma.201700996 ↗
9. 10.2147/IJN.S28752310.2147/IJN.S287523 ↗
10. 10.1021/acsami.0c0942210.1021/acsami.0c09422 ↗
11. 10.1166/jnn.2011.472510.1166/jnn.2011.4725 ↗
12. 10.1002/adhm.20170146010.1002/adhm.201701460 ↗
13. 10.1038/s41551-022-00846-w10.1038/s41551-022-00846-w ↗
14. 10.1021/acsami.1c0566910.1021/acsami.1c05669 ↗
15. 10.1039/D0NR04634E10.1039/D0NR04634E ↗
16. 10.1021/acsnano.0c0437510.1021/acsnano.0c04375 ↗
17. 10.7150/thno.2054810.7150/thno.20548 ↗
18. 10.1002/smll.20210000610.1002/smll.202100006 ↗
19. 10.1016/j.biomaterials.2019.11941910.1016/j.biomaterials.2019.119419 ↗
20. 10.1021/acsami.0c2157910.1021/acsami.0c21579 ↗
21. 10.1016/j.bioactmat.2022.01.01010.1016/j.bioactmat.2022.01.010 ↗
22. 10.1016/j.jconrel.2017.11.03610.1016/j.jconrel.2017.11.036 ↗
23. 10.1039/C8NR07730D10.1039/C8NR07730D ↗
24. 10.1016/j.biomaterials.2019.11957510.1016/j.biomaterials.2019.119575 ↗
25. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
26. 10.1007/s13346-017-0462-810.1007/s13346-017-0462-8 ↗
27. 10.1039/C6AN00773B10.1039/C6AN00773B ↗
28. 10.1021/acsami.0c2281510.1021/acsami.0c22815 ↗
29. 10.1002/adfm.20211335310.1002/adfm.202113353 ↗
30. 10.1016/j.jconrel.2018.10.01210.1016/j.jconrel.2018.10.012 ↗
31. 10.1016/j.actbio.2022.05.03810.1016/j.actbio.2022.05.038 ↗
32. 10.3390/pharmaceutics1308130010.3390/pharmaceutics13081300 ↗
33. 10.1016/j.ejpb.2022.04.00610.1016/j.ejpb.2022.04.006 ↗
34. 10.1016/j.ijpharm.2019.11872410.1016/j.ijpharm.2019.118724 ↗
35. 10.1016/j.ejpb.2016.03.01210.1016/j.ejpb.2016.03.012 ↗
36. 10.1016/j.actbio.2021.05.01610.1016/j.actbio.2021.05.016 ↗
37. 10.1016/j.tiv.2012.06.00610.1016/j.tiv.2012.06.006 ↗
38. 10.1038/s41598-018-34809-610.1038/s41598-018-34809-6 ↗
39. 10.1016/j.addr.2020.01.00310.1016/j.addr.2020.01.003 ↗
40. 10.1080/0265673050020448710.1080/02656730500204487 ↗
41. 10.1039/D2NR01500E10.1039/D2NR01500E ↗
42. 10.1016/j.jconrel.2008.05.00310.1016/j.jconrel.2008.05.003 ↗
43. 10.1016/j.biomaterials.2017.10.04810.1016/j.biomaterials.2017.10.048 ↗
44. 10.1016/j.biomaterials.2018.01.02210.1016/j.biomaterials.2018.01.022 ↗